Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 4, 1997, Pages 685-691

  Brown, J ^a   Haines, S ^a   Wilding, I R ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENEMA; MESALAZINE; PENTETATE TECHNETIUM TC 99M;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DESCENDING COLON; DRUG DISTRIBUTION; FOAM; GAMMA SCINTIGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTAL DRUG ADMINISTRATION; RECTUM; SIGMOID; SUPPOSITORY; TECHNIQUE; TRANSVERSE COLON;

EID: 0030882978     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00193.x     Document Type: Article

References (19)

1. Campieri M, Corbelli C, Gionchetti P, et al. Spread and distribution of 5-ASA colonie foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 1992; 37: 1890-7.
2. Ireland A, Jewell DP. Mechanism of action of 5-aminosalicylic acid and its derivatives. Clin Sci 1990; 78: 119-25.
3. Campieri M, Paoluzi P, D'Albasio G, Brunetti G, Pera A, Barbara L. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. Dig Dis Sci 1993; 38: 1843-50.
4. Wilding IR, Kenyon CJ, Chauhan S, et al. Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 161-6.
5. Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology 1987; 92: 1894-8.
6. Campieri M, de Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of proctitis or distal proctosigmoiditis: A randomised controlled trial. Scand J Gastroenterol 1990; 25: 663-8.
7. Van Bodegraven AA, Boer RO, Lourens J, Tuynman HARE, Sindram JW. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 1996; 10: 327-32.
8. Hardy JG, Wood E, Clark AG, Reynolds JR. Colonic motility and enema spreading. Eur J Nucl Med 1986; 12: 176-8.
9. Wood E, Wilson CG, Hardy JG. The spreading of foam and solution enemas. Int J Pharm 1985; 25: 191-7.
10. Hardy JG, Feely LC, Wood E, Davis SS. The application of γ-scintigraphy for the evaluation of the relative spreading of suppository bases in rectal hard gelatin capsules. Int J Pharm 1987; 38: 103-8.
11. Jay M, Beihn RM, Digenis GA, DeLand FH, Caldwell L, Mlodozeniec AR. Disposition of radiolabelled suppositories in humans. J Pharm Pharmacol 1985; 37: 266-8.
12. Hardy JG, Lee SW, Clark AG, Reynolds JR. Enema volume and spreading. Int J Pharm 1986; 31: 151-5.
13. Farthing MJG, Rutland MD, Clark ML. Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis. Br Med J 1979; 2: 822-4.
14. Swarbrick ET, Loose H, Lennard-Jones JE. Enema volumes as an important factor in successful topical corticosteroid treatment of colitis. Proc R Soc Med 1974; 67: 753-4.
15. Davis SS, Hardy JG, Newman SP, Wilding IR. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur J Nucl Med 1992; 19: 971-86.
16. Hardy JG, Healey JNC, Barnard J, Lamont GL, Whiteman M. Mesalazine foam: A novel approach to rectal therapy. Proceedings 9th Congress of Gastroenterology, Sydney, 1990.
17. Wilding IR, Coupe AJ, Davis SS. The role of γ-scintigraphy in oral drug delivery. Adv Drug Del Rev 1991; 7: 87-117.
18. Hardy JG, Perkins AC. Validity of the geometric mean correction in the quantification of whole bowel transit. Nucl Med Commun 1985; 6: 217-24.
19. Clark ML. A local foam aerosol in ulcerative colitis. Practitioner 1977; 219: 103-4.